Overview

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Status:
Completed

Trial end date:
2014-10-24

Target enrollment:

Participant gender:

Summary

This study was conducted to evaluate narlaprevir (NVR) pharmacokinetics (PK) after a single dose with or without ritonavir (RTV) in cirrhotic Child-Pugh class A patients without active HCV infection versus healthy subjects as well as to assess safety and tolerability of such treatment combination.

Phase:

Phase 1

Details

Lead Sponsor:

R-Pharm

Collaborator:

Ascent

Treatments:

Ritonavir